首页> 外文期刊>Molecular cancer therapeutics >BI1071, a Novel Nur77 Modulator, Induces Apoptosis of Cancer Cells by Activating the Nur77-Bcl-2 Apoptotic Pathway
【24h】

BI1071, a Novel Nur77 Modulator, Induces Apoptosis of Cancer Cells by Activating the Nur77-Bcl-2 Apoptotic Pathway

机译:Bi1071,一种新型Nur77调节剂,通过激活Nur77-Bcl-2凋亡途径诱导癌细胞的凋亡

获取原文
获取原文并翻译 | 示例
           

摘要

Nur77 (also called TR3 or NGFI-B), an orphan member of the nuclear receptor superfamily, induces apoptosis by translocating to mitochondria where it interacts with Bcl-2 to convert Bcl-2 from an antiapoptotic to a pro-apoptotic molecule. Nur77 posttranslational modification such as phosphorylation has been shown to induce Nur77 translocation from the nucleus to mitochondria. However, small molecules that can bind directly to Nur77 to trigger its mitochondrial localization and Bcl-2 interaction remain to be explored. Here, we report our identification and characterization of DIM-CpPhCF3+MeSO3- (BI1071), an oxidized product derived from indole-3-carbinol metabolite, as a modulator of the Nur77-Bcl-2 apoptotic pathway. BI1071 binds Nur77 with high affinity, promotes Nur77 mitochondrial targeting and interaction with Bcl-2, and effectively induces apoptosis of cancer cells in a Nur77- and Bcl-2-dependent manner. Studies with animal model showed that BI1071 potently inhibited the growth of tumor cells in animals through its induction of apoptosis. Our results identify BI1071 as a novel Nur77-binding modulator of the Nur77-Bcl-2 apoptotic pathway, which may serve as a promising lead for treating cancers with overexpression of Bcl-2.
机译:NUR77(也称为TR3或NGFI-B),核受体超家族的孤儿成员,通过转移到线粒体诱导细胞凋亡,其中它与BCL-2相互作用,将BCL-2转化为抗凋亡至促凋亡分子。已显示NUR77诸如磷酸化等磷酸化的后期改性,从而从细胞核到线粒体诱导Nur77易位。然而,可以直接与NUR77联系以触发其线粒体定位和BCL-2相互作用的小分子仍有待探索。在这里,我们报告了我们的鉴定和表征DIM-CPPHCF3 + MESO3-(BI1071),衍生自用于吲哚-3-甲基甲醇代谢物的氧化产物,作为Nur77-Bcl-2凋亡途径的调节剂。 BI1071与高亲和力结合NUR77,促进NUR77线粒体靶向和与BCL-2的相互作用,并有效地在NUR77和BCL-2依赖性方式中诱导癌细胞的凋亡。用动物模型的研究表明,Bi1071通过其诱导细胞凋亡诱导动物中肿瘤细胞的生长。我们的结果鉴定了BI1071作为NUR77-BCL-2凋亡途径的新型Nur77结合调节剂,其可以用作治疗具有Bcl-2的过表达的癌症的有前列铅。

著录项

  • 来源
    《Molecular cancer therapeutics》 |2019年第5期|共14页
  • 作者单位

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

    Sanford Burnham Prebys Med Discovery Inst Canc Ctr La Jolla CA 92037 USA;

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

    Sanford Burnham Prebys Med Discovery Inst Canc Ctr La Jolla CA 92037 USA;

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

    Sanford Burnham Prebys Med Discovery Inst Canc Ctr La Jolla CA 92037 USA;

    Xiamen Univ Sch Pharmaceut Sci Fujian Prov Key Lab Innovat Drug Target Res Xiamen Peoples R;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号